The San Antonio Breast Cancer Symposium is the annual breast cancer conference that brings together researchers, clinicians, patients and manufacturers from all over the world to discuss the latest breast cancer research. While the 2020 symposium was held virtually, there was still an incredible amount of new research shared. Below are some of the highlights:
- Sacituzumab govitecan shows benefit for patients with metastatic triple negative breast cancer: The phase 3 ASCENT trial continues to show that patients with triple negative metastatic breast cancer can benefit from sacituzumab govitecan.
Read more
- Pembrolizumab plus chemotherapy continues to show benefits for patients with triple negative advanced or metastatic breast cancer whose tumours express PD-L1: The KEYNOTE-355 trial showed that the immunotherapy, pembrolizumab, in combination with chemotherapy demonstrated increased progression free survival for patients.
Read more
- Ribociclib continues to show a significant survival benefit for people with HR+/HER2-negative metastatic breast cancer: Research reported that ribociclib, a CDK4/6 inhibitor, significantly improved overall survival while delaying chemotherapy.
Read more
- Real work data continues to show positive results for Palbociclib for the treatment of HR+/HER2-negative metastatic breast cancer: Data from electronic health records show a 48% reduction in the risk of disease progression with the use of palbociclib and letrozole versus letrozole alone.
Read more
- Trastuzumab deruxtecan demonstrated continued efficacy for patients with HER2+ metastatic breast cancer: This phase II clinical trial investigated the use of trastuzumab deruxtecan in patients with HER2+ mBC who had previously received TDM-1 (Kadcyla) and demonstrated an overall response rate of 60.9% with this treatment.
Read more
- Neratinib shows 34% reduction in the risk of disease progression for patients with HER2-positive metastatic breast cancer who had central nervous system (CNS) metastases: In the group of CNS patients the data suggested an improved progression free survival from 5.5 months to 7.8 months.
Read more
- Abemaciclib shows 28% reduction in risk of invasive disease recurrence or death in high-risk early patients with early-stage HR+ breast cancer: The monarchE trial showed that adding abemaciclib to endocrine therapy reduced the risk of invasive disease for patients with HR+, HER2-negative early-stage breast cancer.
Read more
- Women who have had breast cancer may have more difficulty becoming pregnant, but most deliver healthy babies: A meta-analysis showed that while breast cancer survivors may have more challenges becoming pregnant, most will deliver healthy babies and will not experience any detrimental effects on their long-term survival as a result of their pregnancy.
Read more
- Many postmenopausal patients with node-positive breast cancer can avoid chemotherapy: The RxPONDER trial showed that women with HR+/HER2-negative breast cancer that had node involvement may be able to skip chemotherapy without it impacting their disease-free survival. The same trial showed the many premenopausal women still received benefit from adjuvant chemotherapy.
Read more
Photo by The Climate Reality Project on Unsplash
Receive updates by email 
